Grifols S.A. Asset Resilience Ratio
Grifols S.A. asset resilience ratio. Grifols S.A. (GRF) has an Asset Resilience Ratio of 0.04% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Grifols S.A. (GRF) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Grifols S.A. (2005–2024)
Asset resilience ratio of Grifols S.A. from 2005 to 2024. This chart shows how Grifols S.A.'s Asset Resilience Ratio has changed over time. See cash generation quality of Grifols S.A. to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Grifols S.A.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see GRF total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €7.11 Million | 0.04% |
| Total Liquid Assets | €7.11 Million | 0.04% |
Asset Resilience Insights
- Limited Liquidity: Grifols S.A. maintains only 0.04% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Grifols S.A. Industry Peers by Asset Resilience Ratio
Compare Grifols S.A.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Roche Holding AG
SW:ROP |
Drug Manufacturers - General | 9.82% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 6.46% |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3 |
Drug Manufacturers - General | 6.34% |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436 |
Drug Manufacturers - General | 17.40% |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422 |
Drug Manufacturers - General | 8.05% |
Grifols S.A. Asset Resilience Ratio by Year (2005–2024)
Grifols S.A. asset resilience ratio by year from 2005 to 2024. The table below shows the annual Asset Resilience Ratio data for Grifols S.A..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.11% | €24.18 Million ≈ $28.27 Million |
€21.41 Billion ≈ $25.02 Billion |
-0.43pp |
| 2023-12-31 | 0.54% | €116.14 Million ≈ $135.78 Million |
€21.44 Billion ≈ $25.07 Billion |
+0.34pp |
| 2022-12-31 | 0.20% | €43.26 Million ≈ $50.58 Million |
€21.53 Billion ≈ $25.18 Billion |
-10.35pp |
| 2021-12-31 | 10.55% | €2.03 Billion ≈ $2.37 Billion |
€19.23 Billion ≈ $22.49 Billion |
+9.60pp |
| 2020-12-31 | 0.95% | €145.74 Million ≈ $170.38 Million |
€15.27 Billion ≈ $17.86 Billion |
-10.16pp |
| 2019-12-31 | 11.11% | €1.73 Billion ≈ $2.02 Billion |
€15.54 Billion ≈ $18.17 Billion |
+11.11pp |
| 2018-12-31 | 0.01% | €822.00K ≈ $961.00K |
€12.48 Billion ≈ $14.59 Billion |
+0.00pp |
| 2017-12-31 | 0.01% | €702.00K ≈ $820.71K |
€10.92 Billion ≈ $12.77 Billion |
0.00pp |
| 2016-12-31 | 0.01% | €957.00K ≈ $1.12 Million |
€10.13 Billion ≈ $11.84 Billion |
+0.00pp |
| 2015-12-31 | 0.01% | €509.00K ≈ $595.07K |
€9.60 Billion ≈ $11.23 Billion |
0.00pp |
| 2014-12-31 | 0.01% | €476.00K ≈ $556.49K |
€8.45 Billion ≈ $9.88 Billion |
+0.00pp |
| 2013-12-31 | 0.00% | €232.00K ≈ $271.23K |
€5.84 Billion ≈ $6.83 Billion |
-0.29pp |
| 2011-12-31 | 0.29% | €16.90 Million ≈ $19.76 Million |
€5.81 Billion ≈ $6.79 Billion |
-0.39pp |
| 2010-12-31 | 0.69% | €12.95 Million ≈ $15.14 Million |
€1.89 Billion ≈ $2.21 Billion |
+0.19pp |
| 2009-12-31 | 0.50% | €8.22 Million ≈ $9.61 Million |
€1.66 Billion ≈ $1.94 Billion |
-0.07pp |
| 2008-12-31 | 0.56% | €6.66 Million ≈ $7.78 Million |
€1.18 Billion ≈ $1.38 Billion |
-0.19pp |
| 2007-12-31 | 0.75% | €7.08 Million ≈ $8.28 Million |
€939.57 Million ≈ $1.10 Billion |
+0.07pp |
| 2006-12-31 | 0.68% | €6.23 Million ≈ $7.29 Million |
€913.67 Million ≈ $1.07 Billion |
+0.60pp |
| 2005-12-31 | 0.08% | €661.00K ≈ $772.78K |
€821.68 Million ≈ $960.63 Million |
-- |
About Grifols S.A.
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, u… Read more